Genprex, Inc. 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. Although the request references 2023 Q4, this filing is an annual Form 10-K covering the full fiscal year. Genprex is a clinical-stage gene therapy company with no approved products and no product-sales revenue.
Business Context and Development Status
- Oncology: Lead candidate REQORSA (quaratusugene ozeplasmid; formerly GPX-001) uses the non-viral ONCOPREX Delivery System to deliver the TUSC2 tumor-suppressor gene. Development focuses on combinations for non-small cell lung cancer and small cell lung cancer.
- Acclaim-1: Phase 1 dose escalation completed in May 2023 with no dose-limiting toxicities. The recommended Phase 2 dose was 0.12 mg/kg. Phase 2a expansion opened and the first patient was treated in January 2024; interim analyses are expected in early 2025.
- Acclaim-2: Phase 1 dose escalation of REQORSA plus Keytruda was enrolling at 0.06 mg/kg. Completion of dose escalation was expected in the second half of 2024, followed by Phase 2a expansion.
- Acclaim-3: Phase 1 enrollment for REQORSA plus Tecentriq maintenance therapy in extensive-stage small cell lung cancer opened in January 2024. Phase 2 expansion was expected to begin in the second half of 2024.
- Regulatory designations: REQORSA combinations in Acclaim-1, Acclaim-2 and Acclaim-3 have FDA Fast Track Designation. REQORSA received FDA Orphan Drug Designation for small cell lung cancer in August 2023.
- Diabetes: GPX-002 remains preclinical for Type 1 and Type 2 diabetes. The company finalized the construct, continued University of Pittsburgh research and planned additional nonclinical work before seeking further FDA guidance for IND-enabling studies.
Financial Performance and Liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue in either period |
| Research and development expense | $17.6 million | $11.5 million | Up 53% |
| General and administrative expense | $13.4 million | $12.3 million | Up 9% |
| Total costs and expenses | $31.1 million | $23.8 million | Up 30% |
| Operating loss | $31.1 million | $23.8 million | Higher loss |
| Interest income | $215,109 | $90,098 | Higher interest rates and cash balances |
| Net loss | $30.9 million | $23.7 million | Up 30% |
| Net loss per share | $22.56 | $19.80 | Basic and diluted |
| Cash used in operating activities | $24.7 million | $17.6 million | Up 40% |
| Cash provided by financing activities | $10.6 million | $6,426 | Primarily 2023 registered offerings |
| Cash and cash equivalents at year-end | $6.7 million | $21.0 million | Down $14.2 million |
| Accumulated deficit | $133.7 million | $102.8 million | Increased by $30.9 million |
| Debt | None | None | No interest expense |
R&D spending increased primarily because of expanded manufacturing and testing, the transition to more capable contract development and manufacturing organizations, and support for the Acclaim-1 and Acclaim-2 programs. Share-based compensation totaled approximately $5.4 million in 2023.
Management estimated that year-end cash would fund current operations and planned clinical activities into the third quarter of 2024. The company stated that additional financing would be required and that the conditions raise substantial doubt about its ability to continue as a going concern.
Material Changes Versus the Prior Comparable Period
- Net loss increased from $23.7 million to $30.9 million, while operating cash use increased from $17.6 million to $24.7 million.
- R&D expense increased substantially as clinical programs advanced and manufacturing activity expanded.
- The company raised approximately $3.6 million in net proceeds in a March 2023 registered direct offering and approximately $6.7 million in a July 2023 registered direct offering, including warrants.
- The prior JMP Securities ATM facility was terminated in December 2023. A new H.C. Wainwright ATM facility was established, but no shares were sold under it during 2023.
- Manufacturing experienced delays during the transition to a new CDMO, but a new REQORSA batch was successfully produced in December 2023 and was expected to support the Acclaim trials.
- FDA granted Fast Track Designation for the Acclaim-3 combination and Orphan Drug Designation for REQORSA in SCLC.
- Internal control over financial reporting remained ineffective because of material weaknesses involving insufficient segregation of duties and inadequate in-house accounting depth.
Guidance, Outlook, Risks and Unusual Items
- Clinical outlook: Management expected Acclaim-1 interim analyses in early 2025, Acclaim-2 dose escalation completion in the second half of 2024, and Acclaim-3 Phase 1 completion and Phase 2 expansion initiation in the second half of 2024.
- Financing outlook: The company expects to raise additional capital through equity offerings, ATM sales, debt financing, collaborations or other transactions. Future financing may be unavailable or may materially dilute existing stockholders.
- Subsequent financing: From January 1, 2024 through the filing date, the company sold 158,474 shares through the ATM for net proceeds of $881,946. On March 21, 2024, it raised approximately $5.8 million net through a registered direct offering involving common stock, pre-funded warrants and common warrants.
- Capital structure: A 1-for-40 reverse stock split became effective February 2, 2024. The March 2024 offering included warrants exercisable for up to 1,542,112 shares and pre-funded warrants exercisable for up to 1,377,112 shares, creating potential future dilution.
- Going concern: The independent auditor included an emphasis regarding substantial doubt about the company’s ability to continue as a going concern. The financial statements contain no adjustments for a potential inability to continue operations.
- Key risks: Clinical failure, regulatory delays or rejection, patient enrollment challenges, manufacturing and CDMO dependence, additional capital requirements, dilution, intellectual-property disputes, competition, adverse gene-therapy events, reimbursement uncertainty and Nasdaq listing compliance.
- Unusual governance and reporting matters: Management concluded that disclosure controls and internal control over financial reporting were ineffective as of December 31, 2023. Remediation efforts were ongoing and had not yet been demonstrated to operate effectively for a sufficient period.
- Related-party exposure: Introgen Research Institute, controlled by Chairman and CEO Rodney Varner’s family trusts, is entitled to a 1% royalty on certain licensed product sales. No product sales occurred in 2023.
- Legal contingencies: The filing states that no pending litigation or other known contingencies were expected to have a material impact on financial condition, results of operations or liquidity.
Important Facts for Investors to Verify
- Whether the company secured sufficient additional financing after the March 2024 offering to fund operations beyond the third quarter of 2024.
- Current cash burn, remaining cash runway and any changes to the going-concern assessment.
- Enrollment progress, safety data and interim efficacy results for Acclaim-1, Acclaim-2 and Acclaim-3.
- Whether the planned 2024 clinical milestones were achieved or delayed.
- Current manufacturing capacity, CDMO performance, product availability and regulatory acceptance of manufacturing changes.
- The extent of dilution from common-stock issuances, pre-funded warrants, common warrants, options and other equity awards.
- Progress in remediating the material weaknesses in internal control over financial reporting.
- Whether REQORSA or GPX-002 obtains regulatory approval; neither product was approved for commercial sale as of the filing date.